2024-03-28T22:46:03Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/144062023-08-31T08:23:48Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2060com_20.500.12105_2052col_20.500.12105_16978col_20.500.12105_16963col_20.500.12105_2061
00925njm 22002777a 4500
dc
Virseda-Berdices, Ana
author
Rojo, David
author
Martinez, Isidoro
author
Berenguer, Juan
author
González-García, Juan
author
Brochado-Kith, Oscar
author
Fernandez-Rodriguez, Amanda
author
Díez, Cristina
author
Hontañon, Víctor
author
Pérez-Latorre, Leire
author
Micán, Rafael
author
Barbas, Coral
author
Resino, Salvador
author
Jimenez-Sousa, Maria Angeles
author
ESCORIAL Study Group
author
2022-03
Background: A better understanding of the evolution of cirrhosis after hepatitis C virus (HCV) clearance is essential since the reversal of liver injury may not happen. We aimed to assess the evolution of plasma metabolites after direct-acting antivirals (DAAs) therapy and their association with liver disease scores in HIV/HCV-coinfected patients with advanced HCV-related cirrhosis. Methods: We performed a prospective study in 49 cirrhotic patients who started DAAs therapy. Data and samples were collected at baseline and 36 weeks after SVR. Metabolomics analysis was carried out using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Inflammation-related biomarkers were analyzed using ProcartaPlex Immunoassays. Results: At 36 weeks after SVR, patients experienced significant decrease in taurocholic acid, 2,3-butanediol, and LPC(18:0); while several phosphatidylcholines (LPC(16:1), LPC(18:1), LPC(20:4), and PC(16:0/9:0(CHO))/PC(16:0/9:0(COH)), 2-keto-n-caproic acid/2-keto-isocaproic acid and N-methyl alanine increased, compared to baseline. The plasma decrease in taurocholic acid was associated with a reduction in Child-Turcotte-Pugh (CTP) (AMR=3.39; q-value=0.006) and liver stiffness measurement (LSM) (AMR=1.06; q-value<0.001), the plasma increase in LPC(20:4) was related to a reduction in LSM (AMR=0.98; q-value=0.027), and the rise of plasma 2-keto-n-caproic acid/2-keto-isocaproic acid was associated with a reduction in CTP (AMR=0.35; q-value=0.004). Finally, plasma changes in taurocholic acid were directly associated with inflammation-related biomarkers, while changes in LPC(20:4) were inversely associated. Conclusions: Plasma metabolomic profile changed after HCV clearance with all oral-DAAs in HIV/HCV-coinfected with advanced HCV-related cirrhosis. Changes in plasma levels of LPC (20: 4), 2-keto-n-caproic acid/2-keto-isocaproic acid, and taurocholic acid were related to improvements in cirrhosis scores and inflammatory status of patients.
Biomed Pharmacother. 2022 Mar;147:112623.
http://hdl.handle.net/20.500.12105/14406
35032770
10.1016/j.biopha.2022.112623
1950-6007
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
Chronic hepatitis C
Cirrhosis
DAAs therapy
HCV elimination
HIV
Metabolomics
Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients